keyword
MENU ▼
Read by QxMD icon Read
search

Cutaneous lymphoma

keyword
https://www.readbyqxmd.com/read/28815289/-aggressive-primary-cutaneous-b-cell-lymphomas-and-novel-ebv-entities
#1
REVIEW
C Lamos, E Dippel
Primary cutaneous large B‑cell lymphomas (PCBLT), EBV-positive large B‑cell lymphomas, not otherwise specified (EBV+ DLBCL, NOS), and primary cutaneous intravascular large B‑cell lymphomas (PCIVLBL) are recognized as cutaneous lymphomas with intermediate to poor prognosis. Differentiation from indolent B‑cell lymphomas or other pathologies of the skin can be complex, both clinically and histologically, but vital for the outcome of the patient. The combination of immunotherapy and polychemotherapy regimens, such as R‑CHOP, has led to significant improvements in prognosis, especially in diffuse large B‑cell lymphomas...
August 16, 2017: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/28812387/reply-to-recent-advances-in-systemic-targeted-therapy-for-cutaneous-t-cell-lymphoma
#2
Teresa Amaral, Claus Garbe
No abstract text is available yet for this article.
August 16, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28805086/brentuximab-vedotin-therapy-for-cd30-positive-cutaneous-t-cell-lymphoma-a-targeted-approach-to-management
#3
Julia J Scarisbrick
CD30-positive primary cutaneous T-cell lymphoma (CTCL) includes mycosis fungoides, anaplastic large-cell lymphoma and lymphomatoid papulosis type A. Brentuximab vedotin (BV) consists of an antibody targeting CD30 with a protease-cleavable linker to vedotin. CD30 binding allows internalization of BV inducing cell-cycle arrest and apoptosis. Response rates >75% with manageable adverse effects in refractory Hodgkin lymphoma and systemic anaplastic large-cell lymphoma led to accelerated approval for both. Phase II studies in CD30-expressing CTCL followed and showed similar efficacy, which was ratified in a Phase III trial of BV versus physician's choice (methotrexate or bexarotene) showing significant improved responses without increase in severe adverse effects although peripheral neuropathy is frequent...
August 14, 2017: Future Oncology
https://www.readbyqxmd.com/read/28803489/recent-advances-in-systemic-targeted-therapy-for-cutaneous-t-cell-lymphoma
#4
Daniel J Lewis, Ellen J Kim, Madeleine Duvic
No abstract text is available yet for this article.
August 14, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28802500/primary-cutaneous-b-cell-lymphomas
#5
REVIEW
Charity B Hope, Laura B Pincus
B-cell lymphomas represent approximately 20% to 25% of primary cutaneous lymphomas. Within this group, most cases (>99%) are encompassed by 3 diagnostic entities: primary cutaneous marginal zone lymphoma, primary cutaneous follicle center lymphoma, and primary cutaneous diffuse large B-cell lymphoma, leg type. In this article, the authors present clinical, histopathologic, immunophenotypic, and molecular features of each of these entities and briefly discuss the rarer intravascular large B-cell lymphoma.
September 2017: Clinics in Laboratory Medicine
https://www.readbyqxmd.com/read/28802499/cutaneous-t-cell-lymphoma
#6
REVIEW
Melissa Pulitzer
Cutaneous T-cell lymphomas comprise a heterogeneous group of diseases characterized by monoclonal proliferations of T lymphocytes primarily involving skin, modified skin appendages, and some mucosal sites. This article addresses the basic clinical, histologic, and immunohistochemical characteristics of this group of diseases, with additional attention to evolving literature on dermoscopy, reflectance confocal microscopy, flow cytometry, and molecular data that may increasingly be applied to diagnostic and therapeutic algorithms in these diseases...
September 2017: Clinics in Laboratory Medicine
https://www.readbyqxmd.com/read/28800143/immunohistochemistry-reveals-an-increased-proportion-of-myc-positive-cells-in-subcutaneous-panniculitis-like-t-cell-lymphoma-compared-with-lupus-panniculitis
#7
Sebastian Fernandez-Pol, Danielle De Stefano, Jinah Kim
BACKGROUND: Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a malignant primary cutaneous T-cell lymphoma that shares significant clinical, histopathologic, and immunophenotypic overlap with lupus erythematosus panniculitis (LEP). METHODS: We performed immunohistochemistry for the MYC oncoprotein on 23 cases of SPTCL (one CD8 negative) and 12 cases of LEP to evaluate if there are quantitative or qualitative differences in protein expression of this marker in these entities...
August 11, 2017: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/28796362/primary-cutaneous-acral-cd8-positive-t-cell-lymphoma-with-extra-cutaneous-involvement-a-long-standing-case-with-an-unexpected-progression
#8
Alberti-Violetti S, Fanoni D, Provasi M, Corti L, Venegoni L, Berti E
Primary cutaneous acral CD8+ T-cell lymphoma (acral CD8+ TCL) is a new provisional entity characterized by acral skin lesions and an indolent course. We describe an extraordinary case characterized by relapsed nodules with CD8+ cytotoxic infiltrates on the left ear. After 35 years, the skin lesions spread to other acral sites, and a mass with the same histological features as the other skin lesions appeared on the nose. Multiple courses of chemotherapy led to stable disease. Histological examinations carried out at different times showed the gradual transformation of the neoplastic cells with an increased proliferation index...
August 10, 2017: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/28795410/clinicopathological-analysis-of-46-cases-with-cd4-and-or-cd56-immature-hematolymphoid-malignancy-reappraisal-of-blastic-plasmacytoid-dendritic-cell-and-related-neoplasms
#9
Yuka Suzuki, Seiichi Kato, Kei Kohno, Akira Satou, Ahmed E Eladl, Naoko Asano, Michihiro Kono, Yuichi Kato, Masafumi Taniwaki, Masashi Akiyama, Shigeo Nakamura
AIMS: Here we aimed to investigate the clinicopathological features of CD4+ and/or CD56+ immature hematolymphoid malignancy (iHLM), including blastic plasmacytoid dendritic cell neoplasm (BPDCN). METHODS AND RESULTS: We analysed the clinicopathological features of 46 patients consecutively diagnosed with CD4+/CD56+ iHLM. These cases were categorized into three groups based on their immunohistochemical expression of three plasmacytoid dendritic cell (pDC) markers (CD123, CD303, and TCL1): cutaneous BPDCN (n = 35), non-cutaneous BPDCN (n = 6), and non-BPDCN-type CD56+ neoplasms (n = 5)...
August 10, 2017: Histopathology
https://www.readbyqxmd.com/read/28795194/-treatment-of-rare-cutaneous-t%C3%A2-cell-lymphoma-and-blastic-plasmacytoid-dendritic-cell-neoplasm
#10
REVIEW
U Wehkamp, M Weichenthal
Among the group of primary cutaneous lymphomas several subtypes have very low incidence rates. Based on the revision of the WHO classification for lymphoid neoplasms (2016), an overview of rare cutaneous T‑cell lymphoma (CTCL) subtypes is given and therapeutic approaches are detailed. The prognosis of the different subtypes is highly variable underlining the importance of adequate stage and subtype adapted treatment. In cases of indolent subtypes topical treatment, e. g. topical corticosteroids or UV phototherapy are often sufficient...
August 9, 2017: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/28793956/hypersensitivity-reaction-to-%C3%AE-lactam-antibiotics-in-patients-with-adult-t-cell-leukemia-lymphoma-treated-with-mogamulizumab%C3%A2
#11
Takeo Yasu, Yoichi Imai, Nobuhiro Ohno, Kaoru Uchimaru, Yosuke Kurokawa, Arinobu Tojo
Mogamulizumab (MOG) is a humanized anti-CCR4 monoclonal antibody that is highly cytotoxic for adult T-cell leukemia/lymphoma (ATL) cells. Most non-hematological adverse events are cutaneous adverse reactions in ATL patients. We reviewed the medical records of 24 patients with CCR4-positive aggressive ATL who had received MOG treatment. The incidence of MOG-induced cutaneous adverse reactions (MCARs) was 25% (6 patients). Four patients with MCAR had an interesting clinical course, compared with MCARs reported in previous reports...
August 10, 2017: International Journal of Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28791248/an-unusual-presentation-of-chronic-lymphocytic-leukemia
#12
Dinesh Atwal, Mihir Raval, Belal Firwana, Jeanette Ramos, Appalanaidu Sasapu
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a B-cell lymphocytic neoplasm with indolent clinical course. If identified early, observation is opted. Many variables lead to the initiation of treatment. Authors describe a 62-year-old male presenting with shortness of breath and found to have white cell count of 1360 × 10(9)/L and subsequently was diagnosed with CLL/SLL. The patient received leukapheresis along with tumor lysis treatment and systemic chemotherapy with fludarabine, cyclophosphamide, and rituximab regimen...
July 2017: Avicenna Journal of Medicine
https://www.readbyqxmd.com/read/28782389/the-effect-of-phototherapy-on-progression-to-tumors-in-patients-with-patch-and-plaque-stage-of-mycosis-fungoides
#13
Joyce W Hoot, Li Wang, Terry Kho, Oleg E Akilov
BACKGROUND: Phototherapy has been a mainstay in the treatment of mycosis fungoides (MF). However, the recent findings of UV-induced p53 mutations in advanced MF suggest that phototherapy may contribute to disease progression. OBJECTIVE: The objective of this study was to evaluate the effect of phototherapy on the time to tumor progression and overall survival in MF. MATERIALS AND METHODS: Retrospective analysis of patients seen at the University of Pittsburgh Cutaneous Lymphoma Clinic from 1979 to 2016...
August 7, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28770576/transformed-waldenstr%C3%A3-m-macroglobulinaemia-clinical-presentation-and-outcome-a-multi-institutional-retrospective-study-of-77-cases-from-the-french-innovative-leukemia-organization-filo
#14
Eric Durot, Cécile Tomowiak, Anne-Sophie Michallet, Jehan Dupuis, Bénédicte Hivert, Stéphane Leprêtre, Elise Toussaint, Sophie Godet, Fatiha Merabet, Eric Van Den Neste, Sarah Ivanoff, Xavier Roussel, Jean-Marc Zini, Caroline Regny, Richard Lemal, Laurent Sutton, Aurore Perrot, Katell Le Dû, Lukshe Kanagaratnam, Pierre Morel, Véronique Leblond, Alain Delmer
Histological transformation (HT) to diffuse large B-cell lymphoma (DLBCL) is a rare and poorly reported complication of Waldenström macroglobulinaemia (WM). We performed a retrospective study of 77 WM patients with biopsy-proven transformation to DLBCL. The median time from WM diagnosis to HT was 4·6 years and 16 patients (21%) had never been treated for WM. At HT, extranodal sites were observed in 91% of patients with a rather high incidence of central nervous system, cutaneous or testicular involvement...
August 2, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28770285/-treatment-of-mycosis-fungoides-and-s%C3%A3-zary-syndrome
#15
REVIEW
J P Nicolay, C Assaf
Adequate therapeutic management of cutaneous T-cell lymphoma (CTCL) requires the identification of the exact CTCL stage and entity within the current WHO classification. There is no curative therapy for CTCL yet, so that treatment currently aims at improving symptoms and quality of life as well as reducing relapse rates. The treatment has to be stage-adapted. Therapeutic options comprise skin-directed as well as systemic treatment. In early stages, phototherapy and local steroids are the first-line therapeutic options...
August 2, 2017: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/28770284/-importance-of-cutaneous-lymphomas-in-clinical-practice
#16
EDITORIAL
C-D Klemke, U Hillen, S Grabbe
No abstract text is available yet for this article.
August 2, 2017: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/28766736/cutaneous-intravascular-nk-t-cell-lymphoma-with-peculiar-immunophenotype
#17
Victoria Alegría-Landa, Félix Manzarbeitia, Maria Gabriela Salvatierra Calderón, Luis Requena, Socorro María Rodríguez-Pinilla
Intravascular lymphoma (IVL) is a rare entity. Most cases are a variant of extranodal diffuse large B-cell lymphoma, and fewer than 10% of the published cases are of T-cell origin. Only intravascular B-cell lymphoma is recognized as a distinct entity in the most recent WHO classification of lymphoproliferative disorders. We describe a case of cutaneous NK/T IVL, with a cytotoxic immunophenotype and EBV positivity. However, our case was immunohistochemically negative not only for TCR-βF1 and TCR-γ (TCR-silent), but also for CD56, making it the first triple-negative NK/T IVL case to be described...
August 2, 2017: Histopathology
https://www.readbyqxmd.com/read/28766547/-breast-implant-associated-anaplastic-large-cell-lymphoma-a-case-report-and-a-review-of-literature
#18
N G Chernova, E E Zvonkov, A M Kovrigina, A B Sudarikov, D S Badmazhapova, N G Gabeeva, T N Obukhova, S R Karagyulyan, V G Savchenko
Breast implant-associated anaplastic large-cell lymphoma will be identified as a separate nosological entity in the 2017 adapted WHO classification due to differences in its clinical presentations, pathogenesis, and prognosis with those of nodal and cutaneous anaplastic large-cell lymphomas. The paper gives a review of the literature and describes the authors' own clinical case of common breast implant-associated anaplastic large-cell lymphoma involving breast tissue, axillary lymph nodes, anterior chest muscles, and bone marrow...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/28766120/-treatment-of-indolent-cutaneous-b%C3%A2-cell-lymphoma
#19
REVIEW
M Wobser
Primary cutaneous B‑cell lymphomas are rarely encountered and represent 25% of all cutaneous lymphomas. Follicular B‑cell lymphoma and marginal zone lymphoma belong to indolent subtypes which as a rule have no systemic dissemination and, thus, a mostly unchanged life expectancy. Therefore, skin-directed treatment options such as excision or radiotherapy are usually sufficient to control the disease. In contrast, cutaneous diffuse large B‑cell lymphoma and EBV-associated B‑cell lymphomas of the skin belong to more aggressive entities which demand a systemic first-line upfront therapy with R‑CHOP...
August 1, 2017: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/28762479/brentuximab-vedotin-in-cd30-primary-cutaneous-t-cell-lymphomas-a-review-and-analysis-of-existing-data
#20
Tyler H Enos, Lawrence S Feigenbaum, Heather W Wickless
BACKGROUND: The utility of brentuximab vedotin (BV) in CD30(+) systemic lymphomas is established, however evidence for treating primary cutaneous lymphoma remains limited. This study aimed to evaluate BV in treating CD30(+) transformed mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (PC-ALCL). METHODS: A literature review was conducted, and we analyzed data from published trials and case reports obtained via search of Ovid-MEDLINE(®) and PubMed databases...
August 1, 2017: International Journal of Dermatology
keyword
keyword
5318
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"